Pharmaceutical companies including AbbVie, Johnson & Johnson, Bristol Myers Squibb, Takeda, and Otsuka’s Astex Pharmaceuticals have pooled proprietary structural data of thousands of protein-ligand interactions to train a large language model enhancing AI-driven drug discovery. Separately, researchers at Integra Therapeutics, in collaboration with Pompeu Fabra University and the Center for Genomic Regulation, have developed synthetic proteins that outperform natural counterparts in editing the human genome, showcasing AI's power to revolutionize genetic engineering. These advancements highlight the convergence of AI, structural biology, and genomics in accelerating therapeutic development.